The Drug That Was Supposed to Keep You Alive

Potassium chloride extended-release capsules are a lifeline. Around 4.5 million patients take nearly 17 million prescriptions of this drug every year in the United States, making it the 35th most commonly prescribed medication in the country. Doctors prescribe it to treat hypokalemia, dangerously low potassium, a condition that itself can disrupt the heart.

The word “extended-release” is critical. It means the drug is engineered to dissolve slowly and steadily so your body gets a controlled, safe dose over time. That controlled release is the entire point. It is what separates medicine from poison.

Glenmark’s capsules were failing the dissolution test. The drug was releasing too quickly, flooding the body with potassium instead of managing it. In the complaint’s own words, Glenmark’s drug “was effectively a rapid-release drug more suitable for an execution rather than the ‘extended-release’ drug the company promised patients.”

The Recall That Came Too Late

On or about June 25, 2024, the FDA revealed that Glenmark was recalling 114 batches of potassium chloride capsules due to “Failed Dissolution Specifications.” The recall covered more than 46 million capsules (enough pills to give every single person in the state of Texas one capsule, with millions left over).

Martha Brewton, a resident of Alabama, had already purchased and taken multiple rounds of this medication in late 2023 and early 2024. She found out from her Walgreens pharmacy, after the fact, that she had been taking adulterated, recalled pills the whole time. She had no way to know. Nobody told her.

The lawsuit argues the dissolution defect was almost certainly present for several years before the recall, based on the size of the affected batches and the expiration date ranges involved. Glenmark may have already sold and patients already consumed batches that expired before the recall even went public.

The Non-Financial Ledger: What Money Can’t Fix

Martha Brewton went to Walgreens to fill a prescription. She trusted the label. She trusted the “USP” designation stamped on the bottle. She paid out of pocket, multiple times, for a drug her doctor prescribed to manage a real, serious health condition. She had no reason to believe the medication in her hand was anything other than what it claimed to be.

She found out from her pharmacy, after the fact, that she had been taking pills that the FDA classified as having a “reasonable probability” of causing death. That is not a hypothetical risk buried in fine print. That is the federal government’s most severe product classification, applied to the exact pills she swallowed.

Think about what that actually means for a moment. You take a pill because your doctor told you to. You take it to stay healthy. And somewhere between the factory floor and your kitchen counter, the company that made it decided that internal quality controls were optional. They knew, based on a documented history of FDA warning letters dating to 2019, that their manufacturing practices were broken. They kept selling anyway.

The people most endangered by this failure are not healthy adults with backup options. The complaint is explicit: patients with hypertension, heart failure, and renal dysfunction face the greatest risk of hyperkalemia from a rapid-release potassium dose. These are the same patients who are most likely to be prescribed potassium chloride in the first place. The sickest, most medically fragile people were handed the most dangerous version of their medication, packaged and labeled as the safe one.

They Sold Pills That Should Have Been Incinerated

Under federal law, adulterated drugs cannot be sold. They must be destroyed. The complaint states this plainly: “Adulterated drugs must be incinerated, not sold for profit.” Every single transaction where a patient paid for one of these capsules was a transaction where they received something legally worth zero dollars in exchange for real money, real insurance claims, and real faith in a system that failed them completely.

The complaint further alleges that Glenmark may have sold additional adulterated batches that had already expired before the recall announcement, meaning those pills will never be part of the official recall count. Patients who took them will never get a notification. They may never know. And Glenmark, the complaint argues, knew or should have known those batches were failing quality standards before they ever reached a pharmacy shelf.

The betrayal embedded in this story runs through every layer of the medical system. Doctors prescribed the drug in good faith. Pharmacists dispensed it in good faith. Patients took it in good faith. Glenmark collected money and, according to the lawsuit, did so while knowing its quality control systems were so broken the FDA had been sending warning letters for years without the company correcting the underlying problems. Both warning letters, the one from October 2019 and the one from November 2022, remain open to this day.

There is a word for a company that manufactures medication, labels it as meeting safety standards it knows it does not meet, sells it to sick people who have no realistic way to verify the claim, and then pockets the revenue while the FDA’s unresolved warning letters pile up on its desk. The word the lawsuit uses is fraud.

Legal Receipts: Straight From the Documents

These are direct quotes and factual statements from the filed complaint. No paraphrasing. No spin. Just what the lawyers put on record.

“According to Glenmark’s press release, the defect ‘may cause high potassium levels, also known as hyperkalemia, which can result in irregular heart beat that can lead to cardiac arrest.’ Patients ‘who require chronic use of potassium chloride extended-release oral capsules, especially in those patients with underlying comorbidities or conditions that cause altered excretory mechanisms for potassium such as hypertension, heart failure, or renal dysfunction, there is a reasonable probability of developing hyperkalemia that may lead to’ consequences including ‘cardiac arrythmias, severe muscle weakness, and death.'” — Brewton v. Glenmark, Complaint ¶10 — quoting Glenmark’s own press release

“In practice, Glenmark’s drug was effectively a rapid-release drug more suitable for an execution rather than the ‘extended-release’ drug the company promised patients.” — Brewton v. Glenmark, Complaint ¶12

“Glenmark’s adulterated drugs were worth zero dollars. Adulterated drugs must be incinerated, not sold for profit. Glenmark must therefore reimburse purchasers who did not receive the benefit of their bargain.” — Brewton v. Glenmark, Complaint ¶17

“This was not Glenmark’s first or only serious quality deficiency. Since 2019, Glenmark has received two FDA warning letters citing the company for ‘significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals,’ rendering the company’s drugs ‘adulterated within the meaning of’ the Food, Drug, and Cosmetic Act. Both warning letters remain open, demonstrating that Glenmark has yet to correct these serious problems.” — Brewton v. Glenmark, Complaint ¶19

“Glenmark’s overall course of conduct shows that it has chronically and systemically chosen to put its own profits ahead of patient health and safety. For Plaintiff and all members of the Class she seeks to represent, Glenmark enriched itself by selling worthless, adulterated prescription medication based on affirmative misrepresentations that its potassium chloride had the required quality that patients expect and on which they are entitled to rely.” — Brewton v. Glenmark, Complaint ¶21

“On information and belief, it is likely that Glenmark sold adulterated potassium chloride that was not included in the recalls because it had already expired by the time Glenmark’s defects became public. Glenmark knew or should have known that any such potassium chloride failed to meet the required USP, CGMP, and therapeutic equivalence standards, yet Glenmark nevertheless chose to sell it based on the false representation that the medicine was compliant.” — Brewton v. Glenmark, Complaint ¶18

Societal Impact: The Ripple Effect of Corporate Negligence

Public Health: When the Medicine Supply Cannot Be Trusted

Potassium chloride is ranked the 35th most commonly prescribed drug in the United States. It is basic, essential infrastructure for millions of sick people. When a manufacturer of a drug this common and this critical operates with broken quality controls for years, the damage reaches far beyond one product recall.

The specific patients endangered here are not a random cross-section of the public. The complaint makes clear that patients with hypertension, heart failure, and renal dysfunction face the “reasonable probability” of hyperkalemia, cardiac arrhythmia, severe muscle weakness, and death from these failed capsules. These are patients whose underlying conditions already put them at elevated cardiovascular risk. Glenmark’s defective rapid-release pills arrived at their most dangerous moments.

The complaint also raises a deeply troubling possibility: Glenmark sold adulterated batches that expired before the recall became public. Those patients took those pills. They were never notified. They will never receive a refund. The true scope of health exposure from this manufacturing failure may be permanently unknowable.

Beyond the immediate patients, the recall erodes systemic trust. Physicians “cannot be expected to test individual drugs,” and patients are “even less able to discern drug quality.” The entire healthcare supply chain, from doctor to distributor to pharmacy to patient, depends on manufacturers telling the truth about what is in the bottle. When a company like Glenmark lies about that for years, every link in that chain breaks.

Economic Inequality: Generic Drugs, Rich Profits, Poor Patients

Generic drugs exist because branded medications are too expensive for most people. The entire social contract of the generic drug market is that you sacrifice brand-name prestige for an equivalent, safe, affordable product. Glenmark’s USP designation was the proof of that contract. It was a promise, stamped on the bottle, that this cheaper pill works exactly the same as the branded version.

Glenmark broke that promise. The “USP” label was false. The drug was adulterated. And yet every patient who paid out-of-pocket, like Martha Brewton who paid multiple times in late 2023 and early 2024, handed over real money for something the lawsuit describes as legally worth zero dollars ($0, the value of a drug that by law must be destroyed, not sold). Their insurance companies also paid for pills that never should have reached a pharmacy shelf, driving up costs across the system.

The lawsuit estimates there are tens of thousands of Alabama class members alone who could each be entitled to the greater of their actual damages or $100 (enough to cover a week of groceries for a family of four) under Alabama’s Deceptive Trade Practices Act, plus treble damages and attorney’s fees. The class action structure exists precisely because individual damages here are too small for any one person to sue over alone. That is how corporations calculate it. Make each individual loss small enough that fighting back costs more than the loss itself, and collect billions in aggregate.

Glenmark has been marketing potassium chloride in the United States since at least 2016, and for a substantial portion of that time the company was doing so while failing basic manufacturing standards that the FDA had already formally cited them for. The revenue generated from selling defective product to insured and uninsured patients alike funded operations at a company that, according to the complaint, “has chronically and systemically chosen to put its own profits ahead of patient health and safety.”

What Now? Fight Back.

The People Still Running This Company

The source documents do not name specific Glenmark executives by personal name in the complaint. What the documents do establish is an organizational structure: Glenmark Pharmaceuticals Inc., USA operates as the North American arm of Glenmark Pharmaceuticals, a multinational company headquartered in Mumbai, India, with US headquarters at 750 Corporate Drive, Mahwah, New Jersey 07430. The company’s North American leadership coordinated the manufacture, marketing, and distribution of the defective pills. Both FDA warning letters against the company remain unresolved.

Regulatory Bodies With Power to Act

• FDA
• DOJ
• FTC
• State AGs
• CFPB

The FDA Has Leverage It Has Not Used

The FDA issued two open warning letters to Glenmark, in October 2019 and November 2022. Both remain open. That means the FDA has formally told Glenmark its manufacturing practices are illegal, and Glenmark has not fixed them, and the FDA has allowed the company to keep selling drugs in the United States anyway. The agency has authority to halt imports, demand consent decrees, and escalate to criminal referrals to the DOJ. Those tools exist. The question is whether regulators use them.

How to Push Back Right Now

If you or someone you know took Glenmark potassium chloride in 2023 or 2024, contact a class action attorney. The lawsuit is already filed. The class is open. You may be entitled to damages, and you do not have to fight this alone. Beyond the courtroom, contact your state attorney general and demand they investigate Glenmark’s sales in your state. File a MedWatch report with the FDA. Reach out to local mutual aid networks that support patients navigating medical costs from pharmaceutical failures. Share this article. The only thing corporations like Glenmark fear more than a lawsuit is a public that refuses to stay quiet.